090729-Xention-web-top-#105

Welcome to Xention

Xention is developing novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development.

The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.

 

 

home-small

home-image-b

Xention Introduces Metrion Biosciences, a Specialist Ion Channel Screening Business

13 May 2015

Xention Limited, announced today the launch of Metrion Biosciences, a contract screening business focused on providing comprehensive and high quality ion channel services to the pharma and biotech industry.
Read More


Xention commences first phase 2 study

01 September 2014

Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation
Read More


Xention awarded £1.4m from Technology Strategy Board

24 July 2014

Xention awarded £1.4m from Technology Strategy Board to develop new medicines for atrial fibrillation
Read More